Prognostic value of miR-106a and miR-20a in AML patients with chemotherapy or allo-HSCT treatment.
1/5 보강
[BACKGROUND] MiR-106a and miR-20a (miR-17 family members) are frequently dysregulated in carcinogenesis, but their prognostic significance in acute myeloid leukemia (AML) remains unclear.
- 표본수 (n) 188
APA
Liu Y, Liu J, et al. (2025). Prognostic value of miR-106a and miR-20a in AML patients with chemotherapy or allo-HSCT treatment.. Hematology (Amsterdam, Netherlands), 30(1), 2533577. https://doi.org/10.1080/16078454.2025.2533577
MLA
Liu Y, et al.. "Prognostic value of miR-106a and miR-20a in AML patients with chemotherapy or allo-HSCT treatment.." Hematology (Amsterdam, Netherlands), vol. 30, no. 1, 2025, pp. 2533577.
PMID
40699038 ↗
Abstract 한글 요약
[BACKGROUND] MiR-106a and miR-20a (miR-17 family members) are frequently dysregulated in carcinogenesis, but their prognostic significance in acute myeloid leukemia (AML) remains unclear.
[METHODS] We analyzed miR-106a and miR-20a expression in bone marrow from 115 AML patients and 45 healthy controls using qRT-PCR. Additionally, we utilized TCGA data (n=188) to assess the association of these miRNAs with clinical factors and outcomes. Prognostic analysis evaluated the impact of miR-106a and miR-20a on overall survival (OS) and event-free survival (EFS). Differentially expressed genes (DEGs) were identified using Limma. GO and KEGG pathway analyses were performed by DAVID. GSEA and PPI were constructed using ClusterProfiler and STRING database.
[RESULTS] MiR-106a and miR-20a elevated in AML healthy controls. In chemotherapy group, miR-106a or miR-20a predicted poor OS and EFS, with dual-high expression conferring the worst outcome. In allo-HSCT group, miR-106a or miR-20a predicted poor OS but similar EFS, with dual-high cases showing the worst OS. In the miR-106a or miR-20a group, allo-HSCT prolonged OS (but not EFS) chemotherapy. In the miR-106a or miR-20a group, there were no obvious differences in OS or EFS between the chemotherapy and allo-HSCT regimens. Multivariable analyses confirmed miR-106a/miR-20a signature as an independent prognostic marker. Moreover, we identified 706 signature-associated DEGs. Bioinformatic analysis illuminated the involvement of miR-106a and miR-20a in regulating diverse biological processes and signaling pathways.
[CONCLUSIONS] MiR-106a and miR-20a are promising AML prognostic biomarkers for adverse outcome. The combined signature improves risk stratification and guides therapy selection (e.g., allo-HSCT for high-risk cases).
[METHODS] We analyzed miR-106a and miR-20a expression in bone marrow from 115 AML patients and 45 healthy controls using qRT-PCR. Additionally, we utilized TCGA data (n=188) to assess the association of these miRNAs with clinical factors and outcomes. Prognostic analysis evaluated the impact of miR-106a and miR-20a on overall survival (OS) and event-free survival (EFS). Differentially expressed genes (DEGs) were identified using Limma. GO and KEGG pathway analyses were performed by DAVID. GSEA and PPI were constructed using ClusterProfiler and STRING database.
[RESULTS] MiR-106a and miR-20a elevated in AML healthy controls. In chemotherapy group, miR-106a or miR-20a predicted poor OS and EFS, with dual-high expression conferring the worst outcome. In allo-HSCT group, miR-106a or miR-20a predicted poor OS but similar EFS, with dual-high cases showing the worst OS. In the miR-106a or miR-20a group, allo-HSCT prolonged OS (but not EFS) chemotherapy. In the miR-106a or miR-20a group, there were no obvious differences in OS or EFS between the chemotherapy and allo-HSCT regimens. Multivariable analyses confirmed miR-106a/miR-20a signature as an independent prognostic marker. Moreover, we identified 706 signature-associated DEGs. Bioinformatic analysis illuminated the involvement of miR-106a and miR-20a in regulating diverse biological processes and signaling pathways.
[CONCLUSIONS] MiR-106a and miR-20a are promising AML prognostic biomarkers for adverse outcome. The combined signature improves risk stratification and guides therapy selection (e.g., allo-HSCT for high-risk cases).
🏷️ 키워드 / MeSH 📖 같은 키워드 OA만
같은 제1저자의 인용 많은 논문 (5)
- Breast Morphological Comparison Between Anatomic and Round Implant Augmentation: A Prospective Study.
- Latent transforming growth factor beta binding protein 1 (LTBP1): roles as a multifunctional extracellular matrix regulator in human disease - from molecular mechanisms to clinical translation prospects.
- Association between body mass index and outcomes in lymphoma-associated haemophagocytic lymphohistiocytosis: A retrospective multicentre cohort study of Jiangsu Cooperative Lymphoma Group (JCLG).
- Single-cell and spatial transcriptome analysis of breast cancer tumor-associated fibroblast heterogeneity and its mediated remodeling of the tumor microenvironment.
- Spatial omics at the forefront: emerging technologies, analytical innovations, and clinical applications.
🏷️ 같은 키워드 · 무료전문 — 이 논문 MeSH/keyword 기반
- A Phase I Study of Hydroxychloroquine and Suba-Itraconazole in Men with Biochemical Relapse of Prostate Cancer (HITMAN-PC): Dose Escalation Results.
- Self-management of male urinary symptoms: qualitative findings from a primary care trial.
- Clinical and Liquid Biomarkers of 20-Year Prostate Cancer Risk in Men Aged 45 to 70 Years.
- Diagnostic accuracy of Ga-PSMA PET/CT versus multiparametric MRI for preoperative pelvic invasion in the patients with prostate cancer.
- Clinical Presentation and Outcomes of Patients Undergoing Surgery for Thyroid Cancer.
- Association of patient health education with the postoperative health related quality of life in low- intermediate recurrence risk differentiated thyroid cancer patients.